Clinical Outcomes of Administration of Rituximab for Desensitization in Liver Transplant Patients with Preformed Donor-Specific Antibodies: A Single-Center Experience

15 December 2023: Original Paper

Masato Shizuku ^123ABCDEF , Nobuhiko Kurata ^1B , Kanta Jobara ^1B , Yasuhiro Fujimoto ^1B , Yasuhiro Ogura ^1ABCDFG*

DOI: 10.12659/AOT.941456

Ann Transplant 2023; 28:e941456

Table 2 Clinical and pathological outcomes.

Variables	Patients with pDSA		Patients without pDSA (n=97)	p
Variables	Rituximab (+) (n=18)	Rituximab (−) (n=5)	Patients without pDSA (n=97)	p
Clinical outcomes
Infusion reaction related with administration of Rituximab	0	n.a.	n.a.	n.a.
Other adverse events from administration of Rituximab to LT	0	n.a.	n.a.	n.a.
Bacteremia during hospitalization	9	2	35	0.54
CMV infection during hospitalization	8	4	53	0.36
Outcomes (death)	3	0	17	0.62
Detection of de novo DSA after LT	1	0	0	0.06
Pathological finding
ACR (RAI ≥5)	2	0	30	0.09
AMR	0	0	0	n.a.
ACR – acute cellular rejection; AMR – antibody mediated rejection; DSA – donor specific antibody; LT – liver transplantation; n.a. – not available; pDSA – preformed donor specific antibody; RAI – rejection activity index.